The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...

President Donald Trump is expected to announce sweeping tariffs on “all countries" affecting many industries, the likes of ...

Trump’s tariffs on EU goods could slash exports by at least €85 billion, hitting autos and pharmaceuticals hardest. Germany, Denmark and Central Europe face sharp fallout, raising recession risks and ...

Novo Nordisk saw its stock drop 21% year-to-date, pressured by weaker-than-expected obesity drug trial results.

Telehealth firm Hims & Hers Health on Tuesday announced that it plans to sell Eli Lilly’s weight-loss drug. This comes after ...

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. Viking doesn't sell weight ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

Lexicon Pharmaceuticals, headquartered in The Woodlands, announced it will exclusively license its drug LX9851 to the maker ...

The attorneys general sent a letter saying the FDA needs to take action because high demand for the weight loss drugs paired ...